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Objectives: To assess the accuracy of Koelis fusion biopsy for the detection of
prostate cancer and clinically significant prostate cancer in the everyday practice.
Methods: We retrospectively enrolled 2115 patients from 15 institutions in four
European countries undergoing transrectal Koelis fusion biopsy from 2010 to 2017. A
variable number of target (usually 2–4) and random cores (usually 10–14) were carried
out, depending on the clinical case and institution habits. The overall and clinically
significant prostate cancer detection rates were assessed, evaluating the diagnostic role
of additional random biopsies. The cancer detection rate was correlated to
multiparametric magnetic resonance imaging features and clinical variables.
Results: The mean number of targeted and random cores taken were 3.9 (standard
deviation 2.1) and 10.5 (standard deviation 5.0), respectively. The cancer detection rate
of Koelis biopsies was 58% for all cancers and 43% for clinically significant prostate
cancer. The performance of additional, random cores improved the cancer detection
rate of 13% for all cancers (P < 0.001) and 9% for clinically significant prostate cancer
(P < 0.001). Prostate cancer was detected in 31%, 66% and 89% of patients with lesions
scored as Prostate Imaging Reporting and Data System 3, 4 and 5, respectively. Clinical
stage and Prostate Imaging Reporting and Data System score were predictors of
prostate cancer detection in multivariate analyses. Prostate-specific antigen was
associated with prostate cancer detection only for clinically significant prostate cancer.
Conclusions: Koelis fusion biopsy offers a good cancer detection rate, which is
increased in patients with a high Prostate Imaging Reporting and Data System score and
clinical stage. The performance of additional, random cores seems unavoidable for
correct sampling. In our experience, the Prostate Imaging Reporting and Data System
score and clinical stage are predictors of prostate cancer and clinically significant
prostate cancer detection; prostate-specific antigen is associated only with clinically
significant prostate cancer detection, and a higher number of biopsy cores are not
associated with a higher cancer detection rate.
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Introduction
In recent years, mpMRI has become a key element in the
diagnosis and management of PCa.1 The advent of mpMRI-
targeted biopsies has improved the CDR, usually estimated to
be approximately 33%, and in particular the detection of clin-
ically significant cancers.2–6 In-bore mpMRI biopsies are the
most precise, but are also costly, time-consuming and less
reproducible. In contrast, TRUS-mpMRI fusion biopsies
achieve good results with acceptable costs, good reproducibil-
ity and accessibility for the patient. Fusion biopsies have
been shown to be superior to cognitive biopsies, and they are
now routinely carried out when a lesion is detected at
mpMRI.7 However, to date, several challenges exist regarding
the implementation of TRUS-mpMRI fusion biopsies in clini-
cal practice: among these, the inaccurate reading of mpMRI,
which should be restricted to dedicated radiologists;5 the
presence of approximately 10% of significant cancers invisi-
ble to mpMRI;8 the inaccurate sampling of lesions during
fusion biopsy, as a result of inaccurate segmentation of
mpMRI images or registration;9 and last, but not least,
mechanical error of the device used. Keeping in mind these
limitations, TRUS-mpMRI fusion biopsies are highly utilized
for targeted biopsy of the prostate, using different devices.5
Among these, Koelis has shown a good targeting precision of
<3 mm on prostate phantoms,6 and an acceptable margin of
error also in clinical practice.10 Once the initial learning curve
is completed, biopsies are easily carried out, usually under
local anesthesia. Since the original Koelis Urostation,
technological progress has been made with the new-genera-
tion Koelis Trinity. The aim of the present multicenter,
retrospective study was to assess the accuracy of Koelis
fusion biopsy for the detection of PCa in everyday practice
on a large number of patients, providing data on the reliabil-
ity of the device across different European institutions.
Methods
This was a retrospective, multicenter study including 2115
consecutive patients from 15 institutions in four European
countries (Italy, France, Belgium, the UK), who underwent
transrectal TRUS-mpMRI fusion biopsy with the Koelis sys-
tem between 2010 and 2017. All data were anonymized and
inserted in a global database. All patients had at least one
suspicious lesion at mpMRI. The primary end-points of
study were the overall and clinically significant CDR of
Koelis fusion biopsies. The secondary end-points included
the diagnostic role of additional random biopsies, and the
correlation between PCa and clinical or mpMRI parameters,
and complications of the procedure reported according to
the Clavien–Dindo classification.11 All patients signed
informed consent for the use of clinical information for clin-
ical studies. The study was carried out according to the
STARD.12
mpMRI and biopsy details
mpMRI were carried out in different centers, sometimes inde-
pendent from the institution where the biopsy was carried
out, as often happens in daily practice. Therefore, no data
about the mpMPI protocol used were available. The suspi-
cious lesions were scored according to the PI-RADS classifi-
cation, version 113 up to 2015, and successively version 2.14
Fusion biopsies were carried out with the Koelis system
(Koelis, Meylan, France) using the Koelis Urostation in
88.7% of patients, and the more recent Koelis Trinity in the
remaining 11.3%. A variable number of targeted biopsies
(usually 2–4) and random biopsies (usually 10–14) were car-
ried out, depending on the clinical case, urologist preference
and institution habits. Koelis Trinity system creates a precise
and highly detailed 3-D map of the prostate, showing the
biopsy cores locations and suspicious areas delineated on
MRI or PET sequences. Trinity integrates 3-D ultrasound,
multimodal elastic fusion and Organ-Based Tracking, which
is the only tracking technology available working with
image-based tracking. During the examination, a 3-D TRUS
probe creates a 3-D reference model of the prostate; new
images are taken to register the location of the biopsy needle
at each biopsy. Thanks to the organ-based technology, the
device follows the position of the prostate and not that of the
probe, automatically compensating for patient movement and
prostate deformation. Koelis Urostation is an older mobile
software platform that required a connection and communica-
tion with an external ultrasound system, whereas Koelis Trin-
ity is a fully-integrated platform, more recently released on
the market.
All biopsies in the present study were carried out with a
transrectal approach by experienced urologists dedicated to
fusion biopsy with Koelis (namely, >50 biopsies carried out
with Koelis).
PCa was considered clinically significant in the case of
findings of a Gleason score ≥7 or three or more cores
of Gleason score 6, as suggested by histological criteria of
PRIAS.15
Statistical analysis
Statistical analyses were carried out with SPSS version 20.0
(IBM Corporation, Armonk, NY, USA). The Mann–Whitney
U-test was used to compare the distribution of continuous
variables, whereas the Fisher’s exact and Pearson’s v2-tests
were used to compare proportions of categorical variables. To
identify predictors of PCa detection, univariate logistic regres-
sion was carried out initially to obtain unadjusted hazard
ratios. Subsequently, all statistically significant variables were
put into a multivariate model to obtain adjusted hazard ratios.
Variables of interest for logistic regression were PSA, clinical
stage, target size, number of targets, PI-RADS score and the
number of cores taken. A two-sided P < 0.05 was considered
statistically significant.
Results
Baseline patients’ characteristics
The mean patients’ characteristics are shown in Table 1
together with mpMRI and biopsy features. Most patients
enrolled had negative DRE (76%) and PSA ≤10 ng/mL
(74%). Almost half of the patients were biopsy-na€ıve,
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whereas 4% followed a protocol of active surveillance.
mpMRI targets were single in the majority of cases (83%).
The mean number of targeted and random cores taken were
3.9 (SD 2.1) and 10.5 (SD 5.0), respectively. A variable
number of additional random cores were taken for each
patient; most commonly, a scheme of 12–14 cores was used
(53% of cases), whereas 5% of patients received targeted
biopsies only. The procedure was well tolerated, with only
minor complications reported (all grade II; urinary infection
rate <5%).
Biopsy outcomes
Biopsy outcomes are reported in Table 2. The CDR of Koelis
biopsies was 58% for all cancers and 43% for clinically
significant PCa. When considering targeted biopsies only, the
CDR was 46% for all cancers and 34% for clinically signifi-
cant PCa.
The performance of additional, random cores improved the
CDR of 13% for all cancers and 9% for clinically significant
PCa; in both cases, the differences were statistically signifi-
cant (P < 0.001). Additional, random cores allowed the
detection of an upgrade from Gleason 6 to 7 in 11% of
patients, and from Gleason 7 to 8 in 6% of patients. Only
one patient was upgraded from Gleason 6 to 8. PCa was
detected in 31%, 66% and 89% of patients with lesions
scored as PI-RADS 3, 4 and 5, respectively. Clinically signif-
icant PCa was detected in 17%, 47% and 79% of lesions
scored as PI-RADS 3, 4 and 5, respectively (Fig. 1). An
increase in Gleason score was noted with the increase of PI-
RADS score (Fig. 2). The improvement of CDR as a result
of additional, random cores was shown independently from
the version of PI-RADS used (Table S1); PCa was more
likely to be found in lesions scored as PI-RADS 5 in ver-
sion 1.0 (93.3%), rather than version 2.0 (81.0%; Fig. S1).
Table 1 Baseline patients’ characteristics, mpMRI features and biopsy
details
Patients’ characteristics
Median age, years (range) 66 (41–86)
Mean PSA, ng/mL (SD) 8.4 (7.4)
PSA density (ng/mL) 0.18 (0.19)
DRE
Negative 1195 (76.1%)
Positive 377 (23.9%)
missing 543
Mean prostate volume, cc (SD) 52.7 (27.1)
Median prostate volume, cc (range) 47 (13–226)
Previous biopsies
Biopsy-na€ıve 705 (46.7%)
Previous negative biopsies 741 (49.1%)
Patients in active surveillance 63 (4.2%)
Missing 606
mpMRI features
mpMRI targets for patient
Single 1754 (82.9%)
Multiple 361 (17.1%)
Mean size of targets, mm (SD) 10.6 (7.3)
PI-RADS of targets (maximum score in case of multiple targets)
3 677 (34.2%)
4 902 (45.3%)
5 409 (20.5%)
Missing 127
Biopsy details
Device
Koelis Urostation 1875 (88.7%)
Koelis Trinity 240 (11.3%)
Targeted cores taken
Mean (SD) 3.9 (2.1)
Median (range) 4.0 (1–18)
Random cores taken
Mean (SD) 10.5 (5.0)
Median (range) 12 (0–32)
Random cores taken in addition to targeted cores
0 111 (5.4%)
1–11 654 (31.7%)
12–14 1092 (52.9%)
≥15 208 (10.0%)
Missing 50
Total cores taken
Mean (SD) 14.4 (5.3)
Median (range) 14 (2–50)
Table 2 Biopsy results in terms of PCa and clinically significant PCa
detection, comparing target biopsies only with target + random biopsies
Target
biopsies only
Target + random
biopsies P
PCa detection on biopsy
CDR 965 (45.6%) 1230 (58.2%) <0.001
PCa Gleason score
GS 6 357 (37.3%) 461 (40.1%) 0.14
GS 7 437 (45.7%) 493 (42.8%) 0.25
GS 8–10 162 (16.9%) 197 (17.1%) 0.86
Missing 9 79
PCa detection according to DRE
Negative 494 (65.9%) 664 (69.0%) 0.17
Positive 256 (34.1%) 299 (31.0%) 0.17
Missing 215 266
PCa detection according to size
<10 mm 256 (45.6%) 305 (46.7%) 0.70
≥10 mm 305 (54.4%) 348 (53.3%) 0.70
Missing 404 577
PCa detection according to PI-RADS
3 144 (15.7%) 208 (17.8%) 0.20
4 450 (49.0%) 595 (51.0%) 0.36
5 325 (35.4%) 363 (31.1%) 0.03
Missing 46 64
PCa detection according to previous biopsy
Biopsy na€ıve 371 (52.9%) 420 (48.6%) 0.08
Previous negative
biopsies
299 (42.7%) 393 (45.4%) 0.27
Patients in active
surveillance
31 (4.4%) 52 (6%) 0.16
Missing 264 365
Clinically significant PCa detection on biopsy
Clinically significant
CDR
716 (33.9%) 909 (43.0%) <0.001
Clinically significant PCa detection according to PI-RADS
3 77 (11.3%) 114 (13.2%) 0.29
4 334 (48.9%) 426 (49.4%) 0.84
5 272 (39.8%) 323 (37.4%) 0.36
Missing 33 48
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Predictors of PCa at biopsy
Considering target biopsies only, PSA, positive DRE, target
size ≥10 mm, multiple targets, elevated PI-RADS score and
biopsy-na€ıve status correlated with PCa detection. Multivari-
ate analyses confirmed this association only for positive DRE
and elevated PI-RADS score (Table 3). As for clinically sig-
nificant PCa, multivariate analyses found positive DRE, PI-
RADS score and also PSA to be predictors of PCa detection
(Table 4).
Considering target plus random biopsies, positive DRE and
elevated PI-RADS score were the only predictors of PCa in
multivariate analyses. The number of cores taken was associ-
ated with PCa, but only in univariate analyses (Table 3). As
for clinically significant PCa, PSA, positive DRE and PI-
RADS score were again associated with PCa detection
(Table 4).
Discussion
The technique of prostate biopsy has been revolutionized in
recent years with the advent of mpMRI/TRUS fusion biop-
sies. Among the devices used for this goal, Koelis is sup-
ported by quite robust evidence, showing a CDR ranging
from 48% to 80%.6,7,16–22 When deciding to use a device for
fusion biopsy, its precision, safety and ease of use are essen-
tial parameters to be considered. However, several other fac-
tors must also be taken into account, such as the reliability of
mpMRI, the skill of the operator and the presence of cancers
still invisible to mpMRI.8
Most of the studies published to date on fusion biopsy are
single-center, small-sized and based on mpMRIs carried out
in high-volume centers by dedicated radiologists, thus limit-
ing their reproducibility. To overcome these limitations, our
multicenter study has gathered data from different European
institutions, with the aim to provide data on the accuracy of
Koelis coming from daily practice. All urologists included in
the study were experienced in Koelis fusion biopsy with >50
procedures carried out each, as the influence of experience in
the accuracy of the fusion biopsy has been well demon-
strated.10
It is difficult to assess the real CDR of fusion biopsy, con-
sidering the heterogeneity of devices used. A recent review
found that mpMRI-TRUS image fusion biopsy achieves a
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median detection rate of any PCa of 50.5%, including five
different softwares.4 According to the present results, the
overall CDR of Koelis biopsies is 58%, which is in line with
other studies focused on the Koelis system.7,16,17,20 The CDR
decreases to 42% when focusing only on clinically significant
PCa. However, what PCa is really to be considered as clini-
cally significant? This definition varies greatly between stud-
ies, reflecting the uncertainty of identifying the determinants
of cancer progression on biopsy.4 In the present study, we
considered the finding of Gleason score 7 or more, or more
than two cores of Gleason score 6 as clinically significant,
following the histological criteria of the PRIAS study.15 In
the literature, there is no definitive consensus about the defi-
nition of clinically significant PCa, but we thought it best to
use the criteria that define a cancer to be addressable to active
surveillance or not. When dealing with fusion biopsy, it is
still not clear how to consider multiple positive cores taken
from the same target. Some authors suggest to consider them
as a single positivity, as they come from the same lesion, but
cancer volume and target size must be taken into account. As
there are no clear recommendations in this field, we chose to
consider every single positive core for the assessment of clin-
ically significant PCa. Some other studies used cancer core
length as a surrogate marker of cancer volume, even if the
exact threshold to define the lesion as clinically significant is
not clear.4
Another debated issue is represented by the utility of ran-
dom biopsies in addition to target biopsies. Should we rely
only on target biopsies only? A prospective study of 1003
patients undergoing both targeted (UroNav, Invivo, Gaines-
ville, FL, USA) and standard biopsy found that targeted
biopsy diagnosed 30% more high-risk cancers and 17% fewer
low-risk cancers.23 Nevertheless, it has been reported that up
to 17% of significant PCa is missed by target biopsy only,
prompting the execution of an additional, standard biopsy.8
Nowadays, the combination of target and random biopsies
Table 3 Predictors of PCa detection on target biopsies only and in target + random biopsies
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
PCa detected on target biopsies only
PSA 1.02 (1.00–1.03) 0.003 1.02 (0.99–1.05) 0.57
DRE
Negative Ref – Ref –
Positive 3.00 (2.35–3.83) <0.001 2.49 (1.73–3.57) <0.001
Target size
<10 mm Ref – Ref –
≥10 mm 1.52 (1.19–1.94) 0.001 1.08 (0.81–1.45) 0.56
No. targets
Single Ref – Ref –
Multiple 1.42 (1.13–1.78) 0.002 1.38 (0.95–1.99) 0.08
Maximum PI-RADS score
3 Ref – Ref –
4 3.68 (2.94–4.61) <0.001 2.22 (1.61–3.06) <0.001
5 14.32 (10.58–19.37) <0.001 6.93 (4.64–10.35) <0.001
No. target cores taken 1.02 (0.98–1.06) 0.30 – –
Previous biopsies
No Ref – Ref
Yes 0.62 (0.51–0.76) <0.001 0.75 (0.54–1.06) 0.10
PCa detected on target + random biopsies
PSA 1.02 (1.01–1.04) 0.001 1.02 (0.99–1.05) 0.16
DRE
Negative Ref Ref –
Positive 3.08 (2.34–4.06) <0.001 2.43 (1.65–3.58) <0.001
Target size
<10 mm Ref – Ref –
≥10 mm 1.50 (1.17–1.93) 0.001 0.99 (0.73–1.33) 0.99
No. targets
Single Ref – Ref –
Multiple 1.45 (1.14–1.83) 0.002 1.18 (0.81–1.72) 0.37
Maximum PI-RADS score
3 Ref – Ref –
4 4.37 (3.53–5.42) <0.001 2.21 (1.61–3.02) <0.001
5 17.74 (12.53–25.11) <0.001 8.30 (5.35–12.86) <0.001
No. target + random cores taken 1.03 (1.01–1.05) <0.001 1.04 (0.99–1.10) 0.07
Previous biopsies
No Ref – – –
Yes 0.08 (0.68–1.03) 0.09 – –
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represents the standard for PCa detection; the present study
strengthens this recommendation, showing that additional,
random cores improved the CDR for all PCa of 13%, and
that of clinically significant PCa of 9%. We must keep in
mind that our patients underwent a variable number of ran-
dom biopsies, being less than the usual 12–14 cores in >30%
of the cohort.
A recent study on 564 patients newly diagnosed with PCa
has shown that systematic biopsy over fusion one (UroNav,
Invivo) upgraded PCa from Gleason 6 to 7 in 5%, and from
Gleason 7 to 8 in 1% of patients. The present results, drawn
from a larger series of patients, are quite different, showing
an upgrade from Gleason 6 to 7 in 11% of patients, and from
Gleason 7 to 8 in 6% of patients. A possible explanation for
this diversity might be due to the different populations in the
study: the present series of patients was more heterogeneous
and possibly exposed to a greater risk of harboring a signifi-
cant PCa outside of the lesions detected at the mpMRI, given
that it includes patients whose mpMRIs were not carried out
in the same center of the fusion biopsy, and sometimes inter-
preted by radiologists not dedicated to prostate imaging. The
diagnostic advantage of Koelis fusion biopsy over a standard
biopsy, however, is not in doubt, considering the overall per-
patient CDR of 58%, a percentage much higher than that
reported for standard biopsies, approximately 33–36%.24
A linear relationship has been suggested between PI-RADS
and Gleason score, reflecting the cellular density of the
region of interest.25 Following this lead, the present results
showed a higher probability of finding PCa with an elevated
Gleason score in the case of PI-RADS 4 or 5. The uncer-
tainty of this correlation, however, is highlighted by the non-
negligible proportion of patients harboring PI-RADS 5
lesions that resulted in being Gleason 6 PCa, or no cancer at
all. Sometimes, an intense granulomatous inflammation of the
prostate can mimic an aggressive cancer at mpMRI, as was
noted in some of our 46 patients who were negative at biopsy
Table 4 Predictors of clinically significant PCa detection on target biopsies only and in target + random biopsies
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Clinically significant PCa detected on target biopsies only
PSA 1.03 (1.02–1.05) <0.001 1.05 (1.02–1.08) 0.001
DRE
Negative Ref – Ref –
Positive 3.29 (2.59–4.18) <0.001 3.13 (2.01–4.87) <0.001
Target size
<10 mm Ref – Ref –
≥10 mm 1.67 (1.29–2.15) <0.001 0.93 (0.64–1.35) 0.71
No. targets
Single Ref – – –
Multiple 1.25 (0.99–1.59) 0.05 – –
Maximum PI-RADS score
3 Ref – Ref –
4 4.58 (3.48–6.02) <0.001 2.10 (1.37–3.24) 0.001
5 15.47 (11.30–21.17) <0.001 5.24 (3.13–8.77) <0.001
No. target cores taken 1.08 (1.03–1.13) <0.001 1.05 (1.02–1.08) 0.32
Previous biopsies
No Ref – Ref –
Yes 0.68 (0.55–0.85) 0.001 0.89 (0.61–1.29) 0.55
Clinically significant PCa detected on target + random biopsies
PSA 1.02 (1.01–1.03) 0.002 1.05 (1.02–1.09) 0.001
DRE
Negative Ref – Ref –
Positive 3.07 (2.41–3.91) <0.001 2.58 (1.68–3.97) <0.001
Target size
<10 mm Ref – Ref –
≥10 mm 1.53 (1.20–1.95) 0.001 0.80 (0.56–1.11) 0.24
No. targets
Single Ref – – –
Multiple 1.23 (0.98–1.55) 0.06 – –
Maximum PI-RADS score
3 Ref – Ref –
4 4.42 (3.47–5.61) <0.001 2.03 (1.38–2.98) <0.001
5 18.54 (13.58–25.39) <0.001 5.47 (3.32–9.01) <0.001
No. target + random cores taken 1.02 (1.00–1.03) 0.01 1.00 (0.94–1.05) 0.98
Previous biopsies
No Ref – Ref –
Yes 0.69 (0.56–0.85) 0.001 0.77 (0.54–1.09) 0.15
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even in the presence of PI-RADS 5 lesions. In contrast, some
lesions might have been simply missed by fusion biopsy. To
overcome these diagnostic inaccuracies, continuous feedback
between urologists, pathologists and radiologists dedicated to
fusion biopsy is required to ensure good quality of the proce-
dure. Unfortunately, in everyday clinical practice, it is not
easy to maintain good standards, especially if mpMRIs are
carried out in centers not dedicated to prostate imaging.
When analyzing the correlation between PI-RADS score
and PCa, we have to remember that PI-RADS classification
was updated in 2015; however, the adoption of the new clas-
sification did not affect the present results, with the addition
of random cores still leading to a significant improvement in
CDR. Interestingly, with the adoption of PI-RADS ver-
sion 2.0, more lesions scored as PI-RADS 5 resulted negative
for cancer, possibly reflecting the need for a learning curve in
MRI interpretation by radiologists.
Regarding the predictors of overall cancer detection at
fusion biopsy, only clinical stage and PI-RADS score showed
a significant association at multivariate analyses. It is interest-
ing to remark that the number of cores taken was not a pre-
dictor of PCa detection, adding another point against the old
saturation biopsy. As for the prediction of clinically signifi-
cant cancers, the old, maltreated PSA seems to reacquire an
important diagnostic role, together with the usual clinical
stage and PI-RADS score. On the contrary, target size was
not a strong predictor of cancer, reflecting again the uncer-
tainties of the mpMRI.
To our knowledge, the present study gathered the largest
series of fusion biopsies reported to date, but is not devoid of
limitations, mostly inherent to its retrospective design. The
main limitations were the lack of a control group, the lack of
data regarding mpMRI protocols and types, the lack of a cen-
tral revision of mpMRI images and bioptic specimens, and
the absence of a standardized protocol of random biopsies,
which did not allow a proper comparison between targeted
and systematic biopsies. In contrast, the heterogeneity of our
cohort can be seen as a strength of this study, which shows
the outcomes of Koelis fusion biopsy in everyday practice,
where mpMRIs are carried out in centers with different
degrees of expertise and patients cannot be selected.
In conclusion, under routine conditions, fusion biopsy with
Koelis achieves a good CDR, which increases in patients
with a high PI-RADS score and clinical stage. The perfor-
mance of additional, random cores seems unavoidable for
correct sampling. PI-RADS and clinical stage are the stron-
gest predictors of PCa detection, whereas PSA showed an
association only for clinically significant PCa. The number of
cores taken was not associated with higher CDR.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1. PCa detection according to PI-RADS score ver-
sion 1.0 or 2.0.
Table S1. Biopsy results in terms of PCa and clinically sig-
nificant PCa detection, comparing target biopsies only with
target + random biopsies, stratified as per PI-RADS version
1.0 and 2.0.
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